InforMS: Winter 2020

FEATURED ARTICLES

MORE FROM THIS ISSUE

The Importance of Early and Effective Treatment with DMTs

The Rocky Mountain MS Center and our partners at the Rocky Mountain MS Center at University of Colorado advocate for a fundamental philosophy of maximizing lifelong brain health through early...

Modern Era of Approved MS Disease Modifying Therapies

A timeline of the FDA approval of various disease modifying therapies for multiple sclerosis. 1993 Interferon β-1b SQ (Betaseron®) 1996 Interferon β-1a IM (Avonex® ) 1996 Glatiramer acetate SQ  (GA –...

Highly Effective Treatments with Good Risk/Benefit Ratios

Individualizing treatment according to a patient’s risk profile starting with high-efficacy treatments helps prevent irreversible brain and spinal cord damage, thus leading to better outcomes. First Line: Natalizumab (Tysabri) in JCV...

Patient Assistance Programs: A Vital Resource for Qualified Patients

It’s no secret that many of the most commonly-prescribed MS treatments can be expensive, making access to them difficult for some people living with MS. Understanding this, many pharmaceutical companies...

Changing How the World Treats MS

A Look at Current Research Priorities at the Rocky Mountain MS Center at University of Colorado The Rocky Mountain MS Center at University of Colorado is the home of one...

Disease Modifying Therapies in MS

The following is a current chart of disease modifying therapies approved for the treatment of multiple sclerosis, as of November 2020. Reviewed by Rocky Mountain MS Center Medical Director Dr. Timothy...

Empower MS: Building Resilience

A Lifelong Practice for Coping with Stress and Anxiety As we reflect on the past year, some words and emotions are likely to surface for many of us right away:...

COVID-19 and MS: The Latest from the Rocky Mountain MS Center

EDITOR’S NOTE: Information contained in this article is current as of the time of printing, Nov. 25, 2020. Despite months of precautions, warnings and official guidelines, the COVID-19 pandemic is...